Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ERIC 2018 | Let me introduce you to ERIC: the European Research Initiative on CLL

Paolo Ghia • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia

The European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) is an important organization, working to support research and patient care in the CLL space. Here, current ERIC President, Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, Milan, Italy, discusses the main aims and initiatives of ERIC with us from the ERIC International Meeting 2018, held in Barcelona, Spain.

More from Paolo Ghia

Nemtabrutinib plus venetoclax in R/R CLL: dose escalation and confirmation in the BELLWAVE-010 trial
1:57
Nemtabrutinib plus venetoclax in R/R CLL: dose escalation and confirmation in the BELLWAVE-010 trial
Paolo Ghia • 8 Dec 2025
Treatment options for patients with CLL who have developed resistance to covalent BTK inhibitors
1:15
Treatment options for patients with CLL who have developed resistance to covalent BTK inhibitors
Paolo Ghia • 8 Dec 2025
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
19:55
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
Paolo Ghia • 25 Apr 2025
A study investigating the efficacy of CAR-T therapy in Richter's transformation
1:52
A study investigating the efficacy of CAR-T therapy in Richter's transformation
Paolo Ghia • 27 Sep 2024

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Paolo Ghia • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Paolo Ghia • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Paolo Ghia • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Paolo Ghia • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals